^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
QLH11811
i
Other names: QLH11811
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Qilu Pharma
Drug class:
EGFR inhibitor
Related drugs:
over1year
To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation (clinicaltrials.gov)
P1, N=72, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR C797S
|
QLH11811
2years
To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation (clinicaltrials.gov)
P1, N=72, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
New P1 trial • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR C797S
|
QLH11811
Share via
